News & Events
HCRI Enrolls First Patients into DAPT Study
Four-year, Public Health Study to be Conducted Through an Unprecedented Collaboration between Industry, FDA and Academia
October 2, 2009 - The Harvard Clinical Research Institute (HCRI) announced today that the first patients have been enrolled in the DAPT Study, marking the official initiation of this four-year public health study. The DAPT Study is an independent, large-scale study in size and scope intended to investigate the benefits of 12 versus 30 months of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. The DAPT Study is being conducted through a unique public-private collaboration among a group of manufacturers of stent and antiplatelet medications, the FDA and Harvard Clinical Research Institute. HCRI is the sponsor of the IDE study and is responsible for the scientific conduct of the DAPT Study and independent analysis of the resulting data, and Laura Mauri, M.D., M.S., HCRI’s chief scientific officer, serves as principal investigator of the study. More information can be found at www.DAPTStudy.org.
